Eman Ayaz
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 6
- Infectious Disease Case Reports and Treatments 1
-
- Bacterial Infections and Vaccines 1
- Journals
- The Lancet (6 papers)Respirology Case Reports (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Eman Ayaz
6 papers receiving 1.5k citations
Eman Ayaz's Hit Papers
Peers
Comparison fields: 5 of 79
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Statistics and Probability 45
- Oncology 75
Countries citing papers authored by Eman Ayaz
This map shows the geographic impact of Eman Ayaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eman Ayaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eman Ayaz more than expected).
Fields of papers citing papers by Eman Ayaz
This network shows the impact of papers produced by Eman Ayaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eman Ayaz. The network helps show where Eman Ayaz may publish in the future.
Co-authors
The 2 scholars most cited alongside Eman Ayaz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2026 | 0 |
About Eman Ayaz
Eman Ayaz is a scholar working on Infectious Diseases, Microbiology, Epidemiology, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 7 papers that have together received 1.6k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Infectious Disease Case Reports and Treatments (1 paper), Bacterial Infections and Vaccines (1 paper) and Burkholderia infections and melioidosis (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Statistics and Probability (45 citations) and Oncology (75 citations). Eman Ayaz has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Bavithra Vijayakumar and Eamonn Trainor. Their work appears in journals such as The Lancet and Respirology Case Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.